| Identification | Back Directory | [Name]
Benzo[b][1,8]naphthyridin-5-amine, 2,4,7,9-tetramethyl- (9CI) | [CAS]
309726-06-5 | [Synonyms]
BMH22
BMH-22
BMH 22
2,4,7,9-tetramethyl-5-pyrido[2,3-b]quinolinamine
2,4,7,9-tetramethylpyrido[2,3-b]quinolin-5-amine
(2,4,7,9-tetramethylpyrido[2,3-b]quinolin-5-yl)amine
Benzo[b][1,8]naphthyridin-5-amine, 2,4,7,9-tetramethyl- (9CI) | [Molecular Formula]
C16H17N3 | [MDL Number]
MFCD01871983 | [MOL File]
309726-06-5.mol | [Molecular Weight]
251.33 |
| Hazard Information | Back Directory | [Description]
BMH-22 is an inhibitor of RNA polymerase I. It acts by causing nucleolar stress and showing potent anticancer activity across many tumor types. | [Uses]
BMH-22, a benzonaphthyridin, is a RNA polymerase I (Pol I) transcription inhibitor independent of p53 function. BMH-22 causes reorganization of nucleolar marker proteins consistent with segregation of the nucleolus. BMH-22 destabilizes RPA194 in a proteasome-dependent manner and inhibits nascent rRNA synthesis and expression of the 45S rRNA precursor. BMH-22 shows potent anticancer activity across many tumor types[1]. | [References]
[1] RPA194, rRNA synthesis, 45S Rrna, anticancer
Karita Peltonen, et al. Small molecule BMH-compounds that inhibit RNA polymerase I and cause nucleolar stress. Mol Cancer Ther. 2014 Nov;13(11):2537-46. DOI:10.1158/1535-7163.MCT-14-0256 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|